相关供者移植:移植后环磷酰胺是否消除了HLA不合的不利影响?
研究纳入2143对供受者( haploidentical sibling n=218、offspring n=218、HLA-matched sibling n=1707),比较急性白血病移植结局。18-54岁组haploidentical sibling与HLA-matched sibling除慢性GVHD较低外无显著差异;55-76岁组offspring移植失败率、非复发死亡和总死亡更高。
要点
- 18-54岁组haploidentical sibling移植慢性GVHD低于HLA-matched sibling(HR 0.63,P<.001),其他结局无显著差异。
- 55-76岁组offspring移植失败率14% vs HLA-matched sibling 6%(P=.003),非复发死亡HR 1.48(P=.02),总死亡HR 1.32(P=.003)。
- 作者认为老年受者使用HLA-matched sibling优于offspring,但两组移植平台不同,需前瞻性随机试验验证。
核心结论
- 在老年受者中,使用HLA-matched sibling而非offspring可获得更优结局,但两组移植平台(GVHD预防和移植物类型)存在差异,需前瞻性随机试验验证。
研究设计与样本
- 研究分析了2143对供受者( haploidentical sibling n=218、offspring n=218、HLA-matched sibling n=1707)的急性髓系或淋系白血病移植数据。
- 所有受者均接受钙调神经磷酸酶抑制剂预防GVHD,haploidentical移植受者 additionally 接受高剂量PT-Cy。
- 患者年龄与供受者关系相关:haploidentical sibling供者对应18-54岁患者,offspring供者对应55-76岁患者,因此按两个年龄组分别分析移植结局。
主要发现
- 18-54岁组中,除慢性GVHD外,haploidentical sibling与HLA-matched sibling移植结局无显著差异;慢性GVHD在haploidentical sibling后较低(HR 0.63,P<.001)。
- 55-76岁组中,offspring移植后慢性GVHD较低(HR 0.42,P<.001),但移植失败率较高(14% vs 6%,P=.003)。
- 55-76岁组中,offspring移植后非复发死亡较高(HR 1.48,P=.02),总死亡较高(HR 1.32,P=.003)。
临床怎么用
- 作者认为老年受者使用HLA-matched sibling优于offspring,但需前瞻性随机试验验证。
局限性
- 两组移植平台(GVHD预防和移植物类型)存在差异。
- 需前瞻性随机试验验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We sought to identify whether posttransplantation cyclophosphamide (PT-Cy) reduces or eliminates the detrimental impact of HLA mismatching on outcomes of HLA-haploidentical related donor transplantation for acute leukemia. Data from 2143 donor-recipient pairs (n = 218 haploidentical sibling; n = 218 offspring; n = 1707 HLA-matched sibling) with acute myeloid or lymphoblastic leukemia were studied. All received a calcineurin inhibitor for graft-versus-host disease (GVHD) prophylaxis while high-dose PT-Cy was also given to recipients of haploidentical transplant. Patient age correlated with donor-recipient relationship: haploidentical siblings donated to patients aged 18 to 54 years whereas offspring donated to patients aged 55 to 76 years. Therefore, transplant outcomes were examined separately in the 2 patient age groups. In patients aged 18 to 54 years, there were no significant differences in outcomes except chronic GVHD, which was lower after haploidentical sibling compared to HLA-matched sibling transplant (hazard ratio [HR], 0.63; P < .001). In patients aged 55 to 76 years, despite lower chronic GVHD (HR, 0.42; P < .001), graft failure (14% vs 6%; P = .003), nonrelapse mortality (HR, 1.48; P = .02), and overall mortality (HR, 1.32; P = .003) were higher after transplant from offspring compared with an HLA-matched sibling. These data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring, although there were differences in transplant platforms (GVHD prophylaxis and graft type) between the 2 groups. Validation of these findings requires a prospective randomized trial wherein the transplant platforms can be closely matched.
引用
- Robinson TM, Fuchs EJ, Zhang MJ, et al. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018. PMID: 29794073. doi:10.1182/bloodadvances.2018018291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。